论文部分内容阅读
目的:探讨重组人干扰素α-2b阴道泡腾胶囊联合苦参凝胶治疗宫颈人乳头瘤病毒亚临床感染的疗效及安全性。方法:宫颈HPV亚临床感染患者74例随机分为观察组(n=37例)和对照组(n=37例)。观察组患者予以重组人干扰素α-2b阴道泡腾胶囊联合苦参凝胶治疗;对照组患者单纯予重组人干扰素α-2b阴道泡腾胶囊治疗。连续3个疗程后,观察两组患者的临床疗效及不良反应,并比较随访观察治疗后6个月的临床疗效。结果:治疗3个疗程后,观察组临床总有效率明显高于对照组(P<0.05);两组均未发生严重药物不良反应,两组不良反应发生率比较差异不明显(P>0.05)。治疗后随访6个月,观察组临床总有效率明显高于对照组(P<0.05)。结论:重组人干扰素a-2b阴道泡腾胶囊联合苦参凝胶治疗宫颈HPV亚临床感染的疗效确切,安全性较佳,远期疗效较肯定。
Objective: To investigate the efficacy and safety of recombinant human interferon α-2b vaginal effervescent capsules combined with kushen gel in the treatment of subclinical infection of cervix human papillomavirus (HPV). Methods: 74 cases of cervical HPV subclinical infection were randomly divided into observation group (n = 37) and control group (n = 37). Patients in the observation group were treated with recombinant human interferon α-2b vaginal effervescent capsules combined with kuchong gelatin, while patients in the control group were treated with vaginal effervescent capsules of recombinant interferon α-2b alone. After 3 consecutive courses of treatment, the clinical efficacy and adverse reactions of the two groups were observed, and the clinical effects were observed after 6 months of follow-up. Results: After three courses of treatment, the total clinical effective rate in the observation group was significantly higher than that in the control group (P <0.05). No serious adverse drug reactions occurred in both groups, and the incidence of adverse reactions in the two groups was not significantly different (P> 0.05) . After 6 months of follow-up, the total effective rate in the observation group was significantly higher than that in the control group (P <0.05). Conclusion: The efficacy of recombinant human interferon alpha-2b vaginal effervescent capsule combined with kushen gel in the treatment of cervical HPV subclinical infection is accurate and safe, and the long-term curative effect is more certain.